Allegria Therapeutics is a biotech firm that engages in the research and treatment of allergy and mast cell-mediated inflammatory diseases.
Allegria Therapeutics has raised $1.5M in total funding. The most recent round was Grant. The last funding was announced in April 2026.
Allegria Therapeutics's investors include Forty51 Ventures, Lichtsteiner Foundation, ALK Abelló, HighLight Capital, Eureka Network.
Allegria Therapeutics is headquartered in Basel, Switzerland.
Allegria Therapeutics is a biotech firm that engages in the research and treatment of allergy and mast cell-mediated inflammatory diseases.
Allegria Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Allegria Therapeutics — Funding & Investors." VCBacked, April 17, 2026, https://www.vcbacked.co/company/allegria-therapeutics. Accessed October 28, 2026.
VCBacked. (2026). Allegria Therapeutics — Funding & Investors. Retrieved October 28, 2026, from https://www.vcbacked.co/company/allegria-therapeutics
{{cite web |title=Allegria Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/allegria-therapeutics |website=VCBacked |access-date=October 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated